Skip to content

Long-term efficacy of Mindfulness Based Stress Reduction on Depression and Anxiety, Symptoms and Distress, Health Status, Coping Capacity and Immune Response in Breast Cancer Survivors: A longitudinal Randomized Controlled Trial

Elisabeth Kenne Sarenmalm, Salmir Nasic, Anna-Lena Emanuelsson Loft, Lena B Mårtensson, Per Karlsson

Research Square October 30, 2025 preprint DOI: 10.21203/rs.3.rs-7518570/v1 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Longitudinal
Sample size 166
Population Breast cancer survivors
Duration 5-year follow-up with assessments at baseline, 3 months, 6 months, 1 year, and yearly thereafter up to 5 years
Measures Hospital Anxiety and Depression Scale, Memorial Symptom Assessment Scale, SF-36, Sense of Coherence, NK cell activity, lymphocytes, cytokine concentrations
Topics Anxiety Depression Meditation
Key findings MBSR reduced depression, anxiety, psychological symptoms, global distress, and total symptom burden and improved coping capacity and health status up to 1 year post-intervention, with Cohen's d values around 0.4-0.8. NK-cell activity and lymphocyte counts increased over time in all groups; MBSR showed some modest immune effects, including on CD3-16+56+ NK cells and cytokines IL-6 and IL-8.

Abstract

Abstract Purpose This 5-year longitudinal randomized controlled trial explored the long-term efficacy of a MBSR intervention for psychological and biological response in breast cancer survivors.

Methods: A total of 166 women were randomly assigned into one of 3 groups: MBSR, Active controls and non-MBSR. Data were collected at baseline, 3-months, 6-months and 1-year follow-up, thereafter yearly up to 5-year. The participants completed the Hospital Anxiety and Depression Scale, the Memorial Symptom Assessment Scale, SF-36, and Sense of Coherence. Blood samples were collected and analyzed for NK cells activity, lymphocytes and cytokine concentrations.

Results: The MBSR intervention demonstrated a strong effect in reducing depression (3-months: 0.015;d Cohen =0.5; 1-year: 0.013;d Cohen =0.5), anxiety (1-year: 0.023;d Cohen =0.4), and a strong effect in psychological symptoms (3-months: 0.019;d Cohen =0.4; 1-year: 0.005;d Cohen =0.6), global distress (3-months: 0.013;d Cohen =0.5; 1-year: 0.002;d Cohen =0.6), and total symptom burden (1-year: 0.046;d Cohen =0.4), a very strong effect on mental health (3-months: <0.001;d Cohen =0.7; 6-months: 0.008;d Cohen =0.5; 1-year: <0.001;d Cohen =0.8), vitality (1-year:0.007;d Cohen =0.5), and general health perceptions (1-year: 0.031;d Cohen =0.4). Coping capacity strongly over improved time (3-months: 0.028;d Cohen =0.4; 6-months: 0.044;d Cohen =0.4; 1-year: 0.006;d Cohen =0.6). A significant increase in NK-cell activity as well as for total number of lymphocytes was seen in all study groups with time. A moderate difference in CD3-16 + 56 + NKx10e9/l (3-months: 0.041;d Cohen =0.4), a moderate difference for cytokines IL-6 (6-months: 0.049;d Cohen =0.4) and IL-8 (1-year: 0.039;d Cohen =0.4) were seen.

Conclusions: This RTC showed long-term efficacy in reducing depression, anxiety, psychological symptoms, global distress and total symptom burden, improved coping capacity and health status up to 1-year post-intervention. MBSR also seemed to have some beneficial efficacy on immune status.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Explore topics